A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy Volunteers

Inclusion Criteria:

- Healthy male and female subjects, 40 to 70 years of age inclusive. Healthy status is
defined by absence of evidence any active or chronic disease following a detailed
medical and surgical history, a complete physical examination including vital signs,
12-lead ECG, hematology, blood chemistry, coagulation, serology and urinalysis. Some
medical conditions are allowed that are well controlled by single stable medication

- A BMI between 18.0 to 30.0 kg/m2 inclusive

- Use of highly effective contraception until 6 months after study follow-up visit

- Agree not to donate blood or blood products for transfusion for the duration of the
study and for one year after their dosing

Exclusion Criteria:

- Suspicion of alcohol or drugs abuse addiction using DSM IV criteria

- Regular smoker (> 5 cigarettes, > 1 pipeful or > 1 cigar per day), tobacco users and
subjects on nicotine replacement therapy

- Prior administration of gantenerumab

- Participation in an investigational drug or device study within 60 days before dosing

- Donation of blood over 500 mL within three months before dosing

- Pregnancy or breast-feeding

- Any abnormal skin conditions or potentially obscuring tattoos, pigmentation or
lesions in the area intended for subcutaneous injection

- Any familial history of early onset Alzheimer's disease

- Claustrophobia, presence of pacemakers, aneurysm clips, artificial heart valves, ear
implants, or foreign metal objects in the eyes, skin or body which would
contraindicate an MRI scan